Proteolysis-targeting chimeras (PROTACs) have shown great therapeutic potential by degrading various disease-causing proteins, particularly those related to tumors. Therefore, the introduction of PROTACs has ushered in a new chapter of antitumor drug development, marked by significant advances over recent years. Herein, we describe recent developments in PROTAC technology, focusing on design strategy, development workflow, and future outlooks. We also discuss potential opportunities and challenges for PROTAC research.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acs.jmedchem.2c01555 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cutting-edge lipid-lowering pharmacological therapies: Improving lipid control beyond statins.
Hipertens Riesgo Vasc
January 2025
Hospital Pharmacist Manager, Pharmaceutical Department, Asl Napoli 3 Sud., Italy. Electronic address:
Statins are crucial for both the prevention and management of atherosclerotic cardiovascular disease (ASCVD). However, even with optimized statin therapy, a significant residual risk of ASCVD remains, highlighting the need for innovative approaches to lipid-lowering therapies (LLT) that more effectively target low-density lipoprotein cholesterol (LDL-C) and other atherogenic lipoproteins. Recently, novel pharmacologic agents have been introduced for the management of dyslipidemia.
View Article and Find Full Text PDFHIV and Inflamm-Aging: How Do We Reach the Summit of Healthy Aging?
Top Antivir Med
December 2024
University of Minnesota, Minneapolis, USA.
People with HIV (PWH) are living longer and experiencing a greater burden of morbidity from non-AIDS-defining conditions. Chronically treated HIV disease is associated with ongoing systemic inflammation that contributes to the development of chronic conditions (eg, cardiovascular disease) and geriatric syndromes (eg, frailty). Apart from HIV disease, a progressive increase in systemic inflammation is a characteristic feature of biologic aging, a process described as "inflammaging.
View Article and Find Full Text PDFA review on molecularly imprinted magnetic solid phase extraction emphasizing the analysis of antibiotics in complex matrices:Design, preparation, and application.
J Chromatogr A
January 2025
Fujian Provincial Key Laboratory for Coastal Ecology and Environmental Studies;College of the Environment and Ecology, Xiamen University, Xiamen 361005, PR China. Electronic address:
Magnetic solid phase extraction (MSPE) has been widely employed in the isolation and enrichment of antibiotics in complex matrices because it presents various unique advantages over traditional SPE including simple operation, fast extraction procedure, low cost and eco-friendliness. In recently years, magnetic molecularly imprinted nanoparticles (MMINs) containing highly specific recognition performance have been widely used to specific extraction of antibiotics under the format of MSPE. In this connection, recent advances of MMINs in the analysis of antibiotic residues are reviewed.
View Article and Find Full Text PDFProspects of bovine milk small extracellular vesicles in veterinary medicine.
Res Vet Sci
January 2025
Laboratory of Food and Environmental Hygiene, Joint Department of Veterinary Medicine, Gifu University, Gifu, Japan; Education and Research Center for Food Animal Health, Gifu University (GeFAH), Gifu, Japan; Joint Graduate School of Veterinary Sciences, Gifu University, Gifu, Japan. Electronic address:
Extracellular vesicles (EV), including exosomes or small EV (sEV) derived from biological fluids, such as milk, have garnered increasing interest in veterinary medicine because of their role in the pathophysiology and understanding of the disease status of the host. Bovine milk serves as a rich source of sEV, containing diverse cargoes of nucleic acids, proteins, and lipids, which play a critical role in intercellular communication and regulation of host status. Although it is more difficult to isolate and purify sEV from bovine milk than from human breast milk, challenges persist in enabling the enrichment and analysis of sEV populations, facilitating the elucidation of their functional roles and prognostic potential in cattle diseases.
View Article and Find Full Text PDFA taxonomy of the factors contributing to the overtreatment of cancer patients at the end of life. What is the problem? Why does it happen? How can it be addressed?
ESMO Open
January 2025
Office of Quality and Value, The University of Texas MD Anderson Cancer Center, Houston, USA.
Many patients with cancer approaching the end of life (EOL) continue to receive treatments that are unlikely to provide meaningful clinical benefit, potentially causing more harm than good. This is called overtreatment at the EOL. Overtreatment harms patients by causing side-effects, increasing health care costs, delaying important discussions about and preparation for EOL care, and occasionally accelerating death.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!